NABL:NYSEN-able, Inc. Analysis
Data as of 2026-04-19 - not real-time
$5.20
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Price action: NABL trades at $5.20, well below its 20‑day SMA of $4.77 and 50‑day SMA of $4.88, yet still under the 200‑day SMA of $6.96, indicating a short‑term bearish bias but long‑term downtrend. Technical momentum shows a bullish MACD histogram (+0.08) and an RSI of 60, suggesting limited upside risk of overbought conditions. Valuation: the DCF fair value of $8.93 implies roughly 33% upside, while the forward PE of 10.6 is far cheaper than the industry average PE of 36.7. Fundamentals: revenue grew 11.8% YoY with an impressive 80% gross margin, but operating margin is negative (-1.5%) and trailing EPS remains -$0.09, highlighting earnings pressure. Liquidity: volume is decreasing and average volume exceeds recent trading, flagging modest liquidity concerns.
Catalysts: recent expansion of the Technology Alliance Program (adding Zensec and Atomatik) and a high‑profile partnership with Manchester City bolster the growth narrative and could accelerate adoption of NABL’s security and remote‑management platform. However, analyst sentiment is mixed, with a recent downgrade to Underperform and a “buy” consensus from five analysts. Overall, the stock sits at a valuation discount with upside potential, but execution risk remains elevated.
Catalysts: recent expansion of the Technology Alliance Program (adding Zensec and Atomatik) and a high‑profile partnership with Manchester City bolster the growth narrative and could accelerate adoption of NABL’s security and remote‑management platform. However, analyst sentiment is mixed, with a recent downgrade to Underperform and a “buy” consensus from five analysts. Overall, the stock sits at a valuation discount with upside potential, but execution risk remains elevated.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term SMAs indicating bearish bias
- Bullish MACD histogram and RSI near 60 limiting downside
- Recent partnership announcements providing short‑term sentiment lift
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF‑derived upside of ~33% and forward PE well below industry average
- Revenue growth and high gross margin supporting earnings recovery
- Strategic alliance expansions expanding addressable market
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- Undervalued relative to intrinsic value but current operating losses
- Strong cash generation (operating cash flow $93M) and free cash flow
- Execution risk tied to turning profitability and scaling partnerships
Key Metrics & Analysis
Financial Health
Revenue Growth11.80%
Profit Margin-3.33%
P/E Ratio10.6
ROE-2.18%
ROA1.77%
Debt/Equity53.48
P/B Ratio1.2
Op. Cash Flow$93.2M
Free Cash Flow$90.2M
Industry P/E36.7
Technical Analysis
TrendBearish
RSI59.9
Support$4.14
Resistance$5.25
MA 20$4.77
MA 50$4.88
MA 200$6.96
MACDBullish
VolumeDecreasing
Fear & Greed Index90.21
Valuation
Fair Value$8.93
Target Price$6.95
Upside/Downside33.65%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.06
Volatility50.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.